Digitoxin reduces primary composite vs placebo in HFrEF, with no statistically significant effect on individual components of all-cause mortality or first heart failure-related hospitalization.
Belkis Kaplan, PharmD Resident
Advertisement
Articles by Belkis Kaplan, PharmD Resident
Reduced-dose apixaban maintains efficacy with less bleeding for extended CAT prophylaxis, reinforcing NCCN’s preexisting guidance in intermediate to high-risk cancer patients.
Advertisement
Latest Updated Articles
API-CAT Findings Support Existing NCCN Cancer-Associated VTE GuidancePublished: September 3rd 2025 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
Anitocabtagene Autoleucel Demonstrates Deep, Durable Responses and Improved MRD-Negativity in RRMM
2
Inclisiran, PCSK9s Elicits Sustained LDL-C Reductions in Familial Hypercholestrolemia
3
Delayed Statin Initiation Following Detection of High LDL-C Raises Risk of Heart Attack
4
Biolinq Shine Receives FDA De Novo Classification as First Multi-Analyte Wearable for Type 2 Diabetes
5
